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Vitamin D nuclear receptor (VDR), a ligand-depen-
dent transcriptional regulator, is an important target
for multiple clinical applications, such as osteoporo-
sis and cancer. Since exacerbated increase of cal-
cium serum level is currently associated with VDR
ligands action, superagonists with low calcium
serum levels have been developed. Based on the
crystal structures of human VDR (hVDR) bound
to 1a,25-dihydroxyvitamin D3 and superagonists—
notably, KH1060—we designed a superagonist
ligand. In order to optimize the aliphatic side chain
conformation with a subsequent entropy benefit, we
incorporated an oxolane ring and generated two ste-
reo diasteromers, AMCR277A and AMCR277B. Only
AMCR277A exhibits superagonist activity in vitro,
but is as calcemic in vivo as the natural ligand. The
crystal structures of the complexes between the
ligand binding domain of hVDR and these ligands pro-
vide a rational approach to the design of more potent
superagonist ligands for potential clinical application.
INTRODUCTION
The lipid soluble seco-steroid 1a,25-dihydroxyvitamin D3
(1a,25(OH)2D3), or calcitriol, regulates multiple biological func-
tions, including, cell growth, differentiation, antiproliferation,
apoptosis, adaptive/innate immune responses, bone mineraliza-
tion, and calcium/phosphate homeostasis. 1a,25(OH)2D3, or its
analogs action, is achieved through the binding to its cognate
nuclear vitamin D receptor (VDR), which belongs to the super-
family of steroid/thyroid hormone/retinoid nuclear receptors
(NR) (Laudet and Gronemeyer, 2002). A striking feature of VDR
arises from its various anatomical localizations encompassing
skin, brain, heart, pancreas, kidney, intestine, colon, prostate,
ovary, and breast (Banerjee and Chatterjee, 2003). Conse-
quently, deregulation of VDR action, due to either mutation(s)Chemistry & Biologyin the encoding gene or impairment of VDR-mediated specific
signals, may lead to severe diseases, such as cancers, psoriasis,
rickets, renal osteodystrophy, and autoimmunity (multiple scle-
rosis, rheumatoid arthritis, inflammatory bowel diseases, type I
diabetes; Bouillon et al., 2006; Holick, 2003; Ebert et al., 2006).
Thus, VDR is an exquisite therapeutic target to potentially cure
patients (Campbell and Adorini, 2006). However, routine use of
1a,25(OH)2D3 for clinical applications is hampered by its intrinsic
hypercalemic/hypercalciuric character. To minimize this side
effect, chemical modifications have been made on the A and/
or CD rings or aliphatic chain of the natural ligand to generate
apparently new analogs that were expected to exhibit marked
hypocalcemic/hypocalciuric properties, while maintaining anti-
proliferative properties (Verlinden et al., 2000; Bouillon et al.,
2005; Nagpal et al., 2005). Therefore, chemical synthesis of
new 1a,25(OH)2D3 superagonists is on the leading edge of phar-
maceutical research to eradicate the potential calcification of
soft tissue from patients who have been subjected to chronic
administration of 1a,25(OH)2D3 (Cheskis et al., 2006). With the
aim of fulfilling these biological parameters, vitamin D super-
agonist analogs have been engineered, which are able to mediate
transcriptional activity with a magnitude at least 10-fold higher
than the natural ligand.
1a,25(OH)2D3, or its synthetic analogs bound to VDR, directs
genomic outcomes preferentially as a heterodimer with its obli-
gate partner, retinoid acid X receptor on response element
located in the promoter regions of target genes (Carlberg and
Dunlop, 2006). This specific binding modulates the production
of ARN messenger (transcription) via the interaction with,
a multi-component protein complex, which comprises func-
tional coactivators or repressors, and the basal transcriptional
machinery (Lonard and O’Malley, 2006). VDR activation with
1a,25(OH)2D3 induces its association with the p160 steroid coac-
tivator (SRC) (Onate et al., 1995), cointegrators that remodel
chromatin and mediator complexes (vitamin D interacting pro-
tein) which recruit RNA polymerase to efficiently achieve the ini-
tiation of the transcription, a highly dynamic and orderly regulated
process (Rachez et al., 1999). As a member of the NR superfamily
of transcription factors, VDR harbors a DNA binding domain and
a ligand binding domain (LBD) (Laudet and Gronemeyer, 2002).15, 383–392, April 2008 ª2008 Elsevier Ltd All rights reserved 383
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Structure-Based Design of Vitamin D AnalogThe LBD exerts a crucial regulatory function, because it contains
both the ligand binding pocket (LBP) and the ligand-dependent
transactivation function (AF-2).
Determination of three-dimensional structures of unliganded
or liganded NR, as well as targeted NR mutagenesis, have high-
lighted that LBD undergoes a dramatic conformational change in
response to specific ligand binding (Bourguet et al., 1995;
Renaud et al., 1995). This induced-fit mechanism (mousetrap)
is characterized by the folding back of H12 onto the core
of LBD, thereby creating a hydrophobic cleft together with
surface-exposed residues to facilitate the recruitment of coacti-
vators, concomitantly with the release of corepressors. Resolu-
tion at the atomic level of the ligand-VDR LBD contacts has
already provided significant insights into the structure-function
relationship of the complex (Rochel and Moras, 2006; Yamada
et al., 2003). We previously engineered a VDR LBD that lacks
a flexible insertion domain between helices H1 and H3, and the
resulting mutant bound to 1a,25(OH)2D3 exhibits similar confor-
mation, transactivation ability, and biophysical properties com-
pared to the wild-type counterpart (Rochel et al., 2000, 2001).
Using this information, we have solved the crystal structure of
human VDR (hVDR) in complex with 1a,25(OH)2D3 agonists,
calcipotriol and seocalcitol (Tocchini-Valentini et al., 2004), and
shown that the hVDR LBD complexes adopt the canonical
conformation of all previously reported agonist-bound NR LBD
(Rochel and Moras, 2006); indeed, helix 12 position and confor-
mation are strictly maintained. Similar observations have been
made for some synthetic analogs of 1a,25(OH)2D3 that exhibit
superagonist properties, such as 14-epi analogs of vitamin D,
19-nor-14-epi-23-yne-1a,25(OH)2D3 (TX522) and 19-nor-14,20-
bisepi-23-yne-1a,25(OH)2D3 (TX527), as well as 20-epi-analogs
of 1a,25(OH)2D3, (MC1288) and 20-epi-22-oxa-24a,26a,27a-tri-
homo-11a,25(OH)2D3 (KH1060) (Eelen et al., 2005; Tocchini-
Valentini et al., 2001). These compounds are at least 10 times
more potent in transactivation assays, and act as antiprolifera-
tive agents with a magnitude of several orders higher than
1a,25(OH)2D3 in vitro (Peleg et al., 1995). In all cases, the ligand
is rather tightly bound to the receptor around the A, Seco B, C,
and D rings. In contrast, the 17b-aliphatic side chain is less
constrained (Eelen et al., 2005). Based on these observations,
we propose that a superagonist analog could be designed by
constraining the ligand conformation and strengthening the
intermolecular contacts of the aliphatic side chain with the
VDR LBP.
In this article, we describe the successful structure-based
design of novel analogs of vitamin D. In order to optimize the
aliphatic side chain conformation with a subsequent entropy ben-
efit, we incorporated an oxolane ring and synthesized two stereo
diasteroisomers, AMCR277A(C23S) and AMCR277B(C23R),
with opposite stereochemistry at C23 of the oxolane moiety.
We solved the crystal structure of hVDR LBD bound to each an-
alog. In vitro and in vivo studies showed a drastic difference be-
tween the biochemical/biological effects of AMCR277A versus
AMCR277B, compared with those induced by 1a,25(OH)2D3.
The crystal structures provide an explanation for the superago-
nist activity mechanism of this compound and a rational
approach to designing more potent ligands, which may serve
for direct clinical applications and/or lead to the identification of
new therapeutic targets.384 Chemistry & Biology 15, 383–392, April 2008 ª2008 Elsevier LtdRESULTS
Structure-Based Design of Novel Side Chain Analogs
In the crystal structures of VDR complexed with several agonist
ligands, the ligand is tightly bound to the receptor around the A,
Seco B, C, and D rings (Figure 1A; Rochel et al., 2000; Tocchini-
Valentini et al., 2001, 2004; Eelen et al., 2005). In contrast, the
aliphatic side chain is less constrained, thus allowing alternative
conformations of the side chain for the 1a,25(OH)2D3 and the
20-epi analogs (Figure 1B). A correlation could be made between
the number of favorable intermolecular contacts of aliphatic side
chains with the LBP and the stability of the complex.
Superimposition of the side chain conformations of the VDR-
ligand complexes KH1060 and 1a,25(OH)2D3 shows that the
two lateral side chains exactly coincide, except at the C17 and
C23 positions, where the two directions form a virtual hetero-
cycle (Figure 1B). Based on this structural information, we
designed a novel ligand that would incorporate a rigid ring
system to minimize the entropic loss and maximize the number
of protein-ligand contacts. To achieve this goal, the hybrid
chemical structure of 1a,25(OH)2D3 and KH1060, incorporating
a rigid ring with an oxolane moiety, was synthesized. Due to
the chirality of the atom C23, two epimers were generated,
AMCR277A and AMCR277B, with opposite stereochemistry at
C23 of the oxolane moiety (Figure 1A). Preliminary docking
experiments suggested that AMCR277A and 1a,25(OH)2D3
could adopt a similar conformation, and that additional O21
and C28 atoms made apparently new van der Waals contacts
with the LBP (data not shown). On the other hand, AMCR277B
should adopt a different conformation and induce a change in
the protein structure. To test this hypothesis, we determined
the crystal structures of the hVDR LBD complexes with
AMCR277A and AMCR277B.
Chemical Synthesis of Two Apparently New
Vitamin D Analogs, AMCR277A and AMCR277B
Synthesis of the targets compounds, AMCR277A and
AMCR277B, is summarized in Figure 2, starting with ketone 1
(Ferna´ndez et al., 1992). The Lythgoe convergent approach
was used for the construction of the vitamin D triene system by
coupling ketone 2 with phosphine oxide 3 (Lythgoe, 1980; Kabat
and Radinov, 2001; Mourin˜o et al., 1997). Detailed syntheses of
both chemical compounds are reported in Figure S1 and
elsewhere in the Supplemental Data available with this article
online.
Ligand-Protein Interactions as Observed
in the Crystal Structures
In the crystal structures of both complexes, the protein adopts
the canonical conformation of all previously reported structures
of VDR LBD bound to agonist and superagonist ligands with
helix H12 folded in the agonistic position. Variations involve only
some side chains located at the surface of the protein. When
compared with VDR LBD-1a,25(OH)2D3 complex, the atomic
models show rmsd on the Ca atoms of 0.23 A˚ and 0.24 A˚ for
VDR LBD-AMCR277A and VDR LBD-AMCR277B complexes,
respectively.
Similar to the natural ligand, the analogs are encapsulated
within the ligand pocket. AMCR277A and AMCR277B adopt anAll rights reserved
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Structure-Based Design of Vitamin D Analogelongated conformation, which is also observed in VDR LBD-
1a,25(OH)2D3 and KH1060 complexes (Figures 1B and 3A).
Thus, they form all previously observed contacts contributing
to the tighter ligand-protein contacts. For all four complexes,
the distance between 1-OH and 25-OH varies from 12.8 to
13.1 A˚. The interactions between the protein and the A, Seco
B, C, and D rings are identical, and the hydroxyl groups make
the same hydrogen bonds: 1-OH with Ser-237 and Arg-274;
3-OH with Tyr-143 and Ser-278; and 25-OH with His-305 and
His-397. Some specific contacts of the aliphatic side chains
with VDR LBP are shown in Figure 3B (Val-300, His-305,
Figure 1. Chemical Structures and Confor-
mation of the Bound Ligands 1a,25(OH)2D3,
KH1060 and the Apparently New Ligands
AMCR277A(C23S) and AMCR277B(23R)
(A) Chemical structures of 1a,25(OH)2D3, KH1060,
AMCR277A, and AMCR277B are represented.
(B) Superposition of 1a,25(OH)2D3 (yellow),
HK1060 (magenta), AMCR277A (cyan), and
AMCR277B (green) after superimposed VDR
complexes. Front (left) and side views (right) of
the ligands are shown. Oxygen atoms are red.
Atom numbers of 17b-aliphatic side chain and
hydroxyl groups of 1a,25(OH)2D3 are shown. Co-
ordinates are from 1DB1 (1a,25(OH)2D3) and
1IE8 (KH1060) from the Protein Data Bank.
His-397, Val-418). A novel feature when
compared with 1a,25(OH)2D3 is the addi-
tional van der Waals contact of O21 with
Val-300, which is also present but weaker
in the VDR LBD-AMCR277B complex.
This stronger interaction with Val-300
has also been observed in the VDR LBD
crystal structures with the superagonist
ligands KH1060 and TX522 (Tocchini-
Valentini et al., 2004; Eelen et al., 2005).
Due to the inverse configuration at C23,
the stereoisomer AMCR277B adopts
a different side chain conformation. C23
and C24 are 0.6 and 1.2 A˚ away, res-
pectively, from their positions in the
AMCR277A complex, thereby affecting
their respective contacts. Consequently,
the positions of C25, C26, C27, and 25-
OH are also different, and the direct inter-
action of AMCR277B with activation helix
12 is then weaker (C27–Val-418 of 4.6 A˚).
Relative Binding Affinity
The strength of the interaction of
AMCR277A and AMCR277B for the
hVDR LBD was evaluated by a compara-
tive study against 1a,25(OH)2D3 with
electrospray ionization mass spectrome-
try (ESI-MS) via the measure of their
accelerating cone voltage needed to dis-
sociate 50% of a noncovalent complex in
the gas phase (Vc50). The Vc50 value
reflects the electrostatic and hydrogen-bonding energies, and
is currently used to study ligand binding strength (Rogniaux
et al., 1999; El-Kabbani et al., 2000). Changes in electrostatic
and H-bond contacts upon chemical modification of the ligand
are directly reflected in the ESI-MS data, providing a qualitative
classification of ligands similar to that obtained by classical
competition experiments. The Vc50 values of AMCR277A,
AMCR277B, and 1a,25(OH)2D3 for the hVDR LBD were obtained
from the ESI mass spectra (Figure S2). The Vc50 values at which
half of the species are liganded and half unliganded are 41, 39,
and 38 V for AMCR277A, AMCR277B, and 1a,25(OH)2D3,Chemistry & Biology 15, 383–392, April 2008 ª2008 Elsevier Ltd All rights reserved 385
Chemistry & Biology
Structure-Based Design of Vitamin D Analogrespectively, indicating a relative affinity for hVDR in the order of
AMCR277A > AMCR277Bz 1a,25(OH)2D3. The higher affinity of
AMCR277A is associated with increased contact, as shown in
the crystal structure (Figure 3B).
To test the biological properties of AMCR277A and
AMCR277B, in vitro and in vivo experiments were conducted
by monitoring analog-induced transcriptional activity, cell prolif-
eration arrest/differentiation, and calcium serum level.
AMRC277A and Not AMRC277B Activates
Transcription at 0.1 nM
Previous studies with gene reporter assays have shown that
vitamin D superagonists, including KH1060, have the potency
to stimulate transcription at 100-fold lower concentration than
the natural ligand. Here, inducible VDR-dependent transcrip-
tional activity was quantified with EBNA 293 cells that were tran-
siently cotransfected with a Gal4-VDR LBD expression vector
and the UAS-TATA luciferase reporter construct. Consistent
with previous findings, VDR-mediated transcription occurs in
a dose-dependent manner with 1a,25(OH)2D3 (Figure 4A; Eelen
et al., 2005). We now demonstrate that the analogs exhibit
a drastic difference in their capacity to induce transcription.
Indeed, we show that, at 0.1 nM, VDR LBP-dependent transcrip-
tion activity is 12 times more potent with AMCR277A compared
with AMCR277B or 1a,25(OH)2D3 (Figure 4A). At this concen-
tration, the luciferase activity was barely detectable with
AMCR277B or 1a,25(OH)2D3 as stimulatory agents. Up to
a dose of 10 nM, the fold transcriptional induction was still signif-
icantly greater in the presence of AMCR277A. Thus, AMCR277A
exhibits superagonist properties in mediating transcription, while
AMCR277B acts as 1a,25(OH)2D3.
AMRC277A at 1 nM Induces HL60 Cell Proliferation
Arrest and Differentiation In Vitro
Since AMCR277A is a superagonist and AMCR277B is not, we
postulate that this biochemical effect may induce specific cell
phenotype. To test this hypothesis, we used the human cell
Figure 2. Summary of the Convergent Syntheses of the Targets
Vitamin D3 Analogs
Synthesis of the targets compounds AMCR277A(C23S) and AMCR277B(C23R)
starts with the ketone 1. The Lythgoe convergent approach was used for the
construction of the vitamin D triene system by coupling ketone 2 with phosphine
oxide 3.
Figure 3. Detailed Structural Representa-
tion of Both Analogs Alone or Bound to
hVDR LBD
(A) The dA-weighted Fo  Fc omit map is shown
contoured at 3.3 d (red). AMCR277A (cyan) and
AMCR277B (green) are shown in stick representa-
tion. Comparison of the ligand conformation of
AMCR277A (cyan) and AMCR277B (green)
are shown after superpimposition. Chiral carbon
atom C23 is marked with asterisks. Oxygen atoms
are colored red.
(B) Close-up view of AMCR277A and AMCR277B
in the VDR LBP. AMCR277A and AMCR277B are
shown in cyan and green, respectively. The resi-
dues, which are closer than 4.0 A˚ and important
for comparison purposes, are shown in yellow.
Specific residues involved in interactions are high-
lighted in magenta. Oxygen and nitrogen atoms
are shown in red and blue, respectively. Hydrogen
bonds of AMCR277A and AMCR277B complexes
are shown in red and blue dotted lines, respec-
tively. Van der Waals bonds of AMCR277A and
AMCR277B complexes are shown in orange and
green dotted lines, respectively. Secondary struc-
ture of VDR is shown in cyan; H3n, H3, H6, H7,
H11, and H12 indicate helices.386 Chemistry & Biology 15, 383–392, April 2008 ª2008 Elsevier Ltd All rights reserved
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(A) AMCR277A, and not AMCR277B or 1a,25(OH)2D3, induces transcription
activity at a dose of 0.1 nM. A total of 293 EBNA cells were transiently
transfected with a UAS-TATA-luciferase reporter plasmid and an expres-
sion plasmid of Gal4 DBD-VDR LBD and subsequently treated with
1a,25(OH)2D3, AMCR277A, or AMCR277B. Luciferase activity for each sample
was normalized to the b-galactosidase activity. Data are shown as fold in-
duction of agonist-induced luciferase activity divided by luciferase activity
of vehicle. Data are presented as mean ± SEM.
(B) AMCR277A-mediated HL60 cell growth arrest is achieved for a dose of
1 nM. HL60 cells were incubated for 96 hr with 1a,25(OH)2D3, AMCR277A
or AMCR277B at various concentrations and counted. Data are presented
as mean ± SEM. **p < 0.01; ***p < 0.001.
(C) AMCR277A-mediated HL60 differentiation into monocyte-like cells is
achieved for a dose of 1 nM. Cells were labeled with PE-labeled anti-humanChemistry & Biologclone HL60, because in vitro culture of HL60 cells in the presence
of 1a,25(OH)2D3 induces proliferation arrest and triggers their
differentiation into a monocyte-like phenotype characterized
by the upregulation of surface marker expression of CD11c
and CD14 (McCarthy et al., 1983; White et al., 2005). HL60 cells
represent a genuine model for the study of the effects of
1a,25(OH)2D3 analogs on the clonal proliferation inhibition of
fresh, acute myeloid leukemic cells harvested from patients
(Pakkala et al., 1995). To determine whether the analogs display
similar responses as the natural ligand, we cultured HL60
cells in vitro with increasing concentrations of AMCR277A,
AMCR277B, or 1a,25(OH)2D3. We monitored proliferation arrest
by live cell enumeration and determined their differentiation sta-
tus by flow cytometry at different time points (Figures 4B and
4C). Our findings indicated that AMCR277B-treated HL60 cells
led to a growth arrest comparable to 1a,25(OH)2D3 at all doses
tested. In sharp contrast, a dose of only 1 nM of AMCR277A re-
sulted in a 45% reduction in cell numbers, whereas no effect was
observed with AMCR277B or 1a,25(OH)2D3. No significant dif-
ference in ligand-induced proliferation arrest was detected for
concentrations higher than 10 nM. Thus, analog AMCR277A
leads to a 10-fold higher HL60 cell proliferation arrest than
1a,25(OH)2D3 or analog AMCR277B.
To test whether the analogs also induce differentiation of HL60
cells, we determined the surface expression level of CD14 and
CD11c by flow cytometry after 96 hr in culture. Cell differentiation
was achieved in the presence of 1a,25(OH)2D3 or the analogs
(Figure 4C). No difference in the production of CDs was observed
with 100 nM saturating concentration of agonists. Consistent
with the increased proliferation arrest observed, AMCR277A
displayed a higher capacity to induce the production of CD11c
and CD14 when compared with 1a,25(OH)2D3 or AMCR277B
at 1 nM. Here, we show that 20.9% of the HL60 cells express
CD11c and/or CD14 upon 96 hr treatment with 1 nM of
AMCR277A, while the percentage was only 7.0 and 5.1 with
1a,25(OH)2D3 and AMCR277B, respectively (Figure 3C). More-
over, a CD11c/CD14 double-positive HL60 subpopulation was
observed only with AMCR277A as agonist, indicating that this
specific stereoisomer is a better inducer of HL60 differentiation
(Figure 4C).
AMCR277B Is Less Calcemic than 1a,25(OH)2D3 while
AMCR277A Behaves Like 1a,25(OH)2D3 In Vivo
Systemic administration of most 1a,25(OH)2D3 analogs induces
hypercalcemia, thereby limiting their use for therapeutic
applications. A lower calcemic action of AMCR277A relative to
that of the natural ligand would enhance its potential clinical
role. Therefore, we examined the in vivo effect of 1a,25(OH)2D3
analogs by monitoring the level of calcium in the serum of male
C57BL/6J mice that were subjected to intraperitoneal injections
for 3 wk with 0.1 or 0.5 mg/kg AMCR277A, AMCR277B, or
1a,25(OH)2D3 versus vehicle.
All mice survived beyond 3 wk after analog treatments (data
not shown). Like 1a,25(OH)2D3, both analogs induce increased
calcium serum level in a dose-dependent manner. Our results
CD11c and FITC-labeled anti-human CD14, and HL60 cell differentiation
was estimated by the double-positive CD11c/CD14 population. Data are
representative of three distinct experiments.y 15, 383–392, April 2008 ª2008 Elsevier Ltd All rights reserved 387
Chemistry & Biology
Structure-Based Design of Vitamin D Analogindicate that AMCR277A is as calcemic as 1a,25(OH)2D3 at 0.1
and 0.5 mg/kg, whereas AMCR277B is significantly less calcemic
compared with the natural ligand (Figure 5).
DISCUSSION
In the present investigation, we designed a 1a,25(OH)2D3 ligand by
incorporating anoxolane ring in the aliphatic sidechain.Asa result,
we generated two 1a,25(OH)2D3 analogs with opposite stereo-
chemistry at C23 of the oxolane moiety (Figure 1). We observed
that, in vitro, AMCR277A(C23S) exhibits specific biological out-
comes compared with AMCR277B(C23R) or 1a,25(OH)2D3 at
two different levels: AMCR277A is a superagonist because it me-
diates transcription more than 10-fold higher than the natural
ligand, and a low dose of AMCR277A significantly inhibits HL60
cell proliferation and further induces their differentiation intomono-
cyte-like cells. However, in vivo studies indicate that AMCR277A-
induced calcium serum increase is similar to that obtained with the
natural ligand.
The two crystal structures provide an explanation for the
higher transactivation potency of AMCR277A (Figures 1B, 3,
and 4A). In this case, the oxolane ring stabilizes a conformation
that mimics the bound form of the natural ligand, adopting the
energetically favorable half-boat conformation that allows
the side chain to fit without further tension as shown in the obser-
ved bond angle of C23-C24-C25 (118), similar to those of
1a,25(OH)2D3 (121
) and KH1060 (118). Further stability is also
provided by the additional van der Waals contact of O21 with
Val-300 (H6). This additional contact with Val-300 is also ob-
served in the complexes formed between VDR and the super-
agonists KH1060 and TX522, but is absent in the complex with
the 20-epi-1a,25(OH)2D3, for which closer contacts with
His-305 and His-397 are observed (Eelen et al., 2005; Toc-
chini-Valentini et al., 2001). In contrast to AMCR277B, the addi-
Figure 5. AMCR277B Is Less Calcemic than 1a,25(OH)2D3 while
AMCR277A Behaves Like 1a,25(OH)2D3 In Vivo
Mice (1 wk-old; 6–7 mice/group) were injected intraperitoneally with
1a,25(OH)2D3, AMCR277A, AMCR277B, or sesame oil as diluent (vehicle) for
3 wk. Doses of analogs that were administrated were 0.1 and 0.5 mg/kg.
Calcium serum level was monitored as described in the Experimental
Procedures. Open circles, control; open triangles, AMCR277A 0.1 mg/kg;
closed triangles, AMCR277A 0.5 mg/kg; open squares, AMCR277B 0.1 mg/kg;
closed squares, AMCR277B 0.5 mg/kg; open diamonds, 1a,25(OH)2D3
0.1 mg/kg; closed diamonds, 1a,25(OH)2D3 0.5 mg/kg. Data are presented as
mean ± SEM.388 Chemistry & Biology 15, 383–392, April 2008 ª2008 Elsevier Ltdtional van der Waals contacts with the LBP are compensated by
the energetically unfavorable planar conformation of the oxolane
ring (torsion angles of O21-C20-C22-C23 and C20-C22-C23-
C28 are 9 and 3, respectively), the larger C23-C24-C25
bond angle (124), and the weaker interaction of C27 with
Val-418 of H12. The apparently new ring fulfills two functions:
a larger fraction of the LBP is occupied by the ligand, thus giving
rise to additional stabilizing contacts, and the active form of the
bound ligand is favored by the ring pucker. Stabilization of an
energetically favorable bound conformation is equivalent to the
selection of an optimal conformer within an ensemble, and has
clear entropic advantages for an induced-fit process (Norman
et al., 2004). This should affect the ligand specificity as well as
the binding kinetics. This stabilized conformation is essential
and specific for VDR-mediated transcription in the presence of
AMCR277A, because the luciferase activity was similar and
very low with either AMCR277B or 1a,25(OH)2D3 (Figure 4A).
The specific 1a,25(OH)2D3 analogs-VDR interactions may
also explain the ability of AMCR277A, and not 1a,25(OH)2D3
or AMCR277B, to inhibit HL60 cell proliferation at a dose of
1 nM (Figure 4C). It should be emphasized that a concentration
of 10 nM AMCR277B or 1a,25(OH)2D3 is required to achieve
similar biological effects as 1 nM of AMCR277A in directing
HL60 phenotype (Figures 4B and 4C). Our results are consistent
with previous findings demonstrating that a dose of 1 nM
1a,25(OH)2D3 is barely able to reduce HL60 cell growth (Pakkala
et al., 1995). In contrast, KH1060, at a concentration even lower
than 1 nM, is able to markedly decrease the division of HL60
cells. Indeed, soft agar culture experiments have shown that
0.1 nM KH1060 for 72 hr reduces the clonal expansion of
HL60 cells by 50%. Consistent with previous findings, we found
that 1 nM KH1060 for 96 hr fully differentiates HL60 cells (data
not shown and Elstner et al., 1996). We now report that 1 nM
of AMCR277A is 5-fold more efficient in inducing HL60
differentiation compared with AMCR277B or 1a,25(OH)2D3
(Figure 4C), highlighting its specific biological action. Since
AMCR277A was designed based on the superimposition of
the side chain conformations of the VDR LBD-ligand complexes
KH1060 and 1a,25(OH)2D3, AMCR277A is likely to act as
a marked antiproliferative molecule in human breast cancer
in vitro, as observed with KH1060 in the estrogen-responsive
MCF-7 adenocarcinoma cell line or the non-estrogen-respon-
sive MDA-MB-231 malignant cells (Elstner et al., 1995). Further
use of AMCR277A for clinical trials and therapeutics applica-
tions is contingent upon its efficiency to achieve physiological
calcium serum level. Our in vivo experiments indicate that
AMCR277A at 0.1 or 0.5 mg/kg is as calcemic as the natural li-
gand, whereas AMCR277B is less calcemic than 1a,25(OH)2D3.
Although AMCR277A is a superagonist and an antiproliferative
molecule, monitoring both cancer growth and calcemic effects
in vivo will allow assessment of its selectivity. It should be
emphasized that the biological activity of both analogs is likely
to be contingent upon the oxidation at C-24 of their side chain
as well as at C-3 of epimerization pathways. The generation of
24-oxo metabolites was not monitored in our study, but their
potential production may lead, per se, to HL60 cell prolifera-
tion/differentiation, since 24-oxo metabolites of 16-ene and
20-epi analogs are as efficient as their parent analogs in direct-
ing cancer cell growth arrest (Reddy et al., 2007).All rights reserved
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ment of the potency and the specificity of the ligand. An easy way
to increase the stability of the complex would be to fill up more of
the LBP, leading to additional contacts between protein and
ligand. A methylation at position C-2 would meet this require-
ment, since the crystal structure of VDR in complex with
1a,25(OH)2D3 shows an empty cavity at this location. Indeed,
we recently solved the crystal structure of hVDR LBD complexes
to 2a-methyl 1a,25(OH)2D3 and showed that the 2a-methyl
group fills a small cavity in the LBD, making additional contacts
with Phe-150, Leu-233, and Ser-237. These bonds are likely
to explain the 4-fold increased affinity of the 2a-methyl-
1a,25(OH)2D3 for VDR and the 2.5-fold increase in inducing
HL60 cell differentiation (Hourai et al., 2006). Therefore, the
methylation at position C-2a of AMCR277A should further in-
crease the superagonist feature of the ligands. The structure-
based design of novel side chain analogs provides a rational
explanation of superagonist activity. We can now compare the
experimental information of several different but closely related
molecules, with a broad spectrum of transactivation potencies,
for which we solved the crystal structures (Rochel et al., 2000;
Tocchini-Valentini et al., 2001, 2004; Eelen et al., 2005; Hourai
et al., 2006; Ciesielski et al., 2007). The crystal structures of
VDR-AMCR277A and VDR-AMCR277B complexes confirm
earlier observations that the conformation of the receptor is not
affected by superagonist ligands (Tocchini-Valentini et al.,
2004; Eelen et al., 2005; Vanhooke et al., 2004). The superago-
nistic activity of AMCR277A can be explained by a combination
of enthalpic effects (additional and tighter intermolecular con-
tacts due to the higher fraction of LBP being occupied) and
entropic effects (energetically favorable, preformed conforma-
tions), resulting in an overall gain both in binding energy and
kinetics. All these factors contribute to a better specificity of
the ligand for VDR. Further structure-based design of even
more potent and specific ligands on the basis of these structural
data can be considered.
In summary, we have generated, to our knowledge, the
first structure-based 1a,25(OH)2D3 superagonist analog,
AMCR277A(C23S). The combination of cell-based assays and
structural analysis showed that this compound is a potent super-
agonist that may serve as a template for the design of even more
efficient superagonists to be used for clinical applications to treat
various types of cancer, including those of the breast and blood.
However, AMCR277A behaves like the natural ligand in terms of
calcemia, preventing its use in vivo. Based on these data, incor-
poration of an oxolane ring in the aliphatic side chain associated
with specific chemical modifications at the C2a of the A ring is
expected to improve the capacity of new analogs to significantly
reduce cell mitosis of malignant cells in vivo. Compelling evi-
dence has shown that selected, substituted 1a,25(OH)2D3 ago-
nists orchestrate the finely tuned recruitment of specific
coactivators (as well as the release of corepressors) to the
VDR to induce chromatin remodeling, facilitating the initiation
of transcription (Banerjee and Chatterjee, 2003). We postulate
that the multiprotein complex scaffold directs the subsequent
transcriptional program and gene activation, in a temporal-regu-
lated manner, which lead to a specific biological outcome,
including HL60 cell growth arrest. The molecular mechanisms
underlying the serum calcium level that may result from rapidChemistry & Biology(nongenomic) or sustained (genomic) effects is still a matter of
debate. Deciphering the structural and molecular mechanisms
that explain the dissociation between the VDR-mediated geno-
mic effects from the calcemic effects is expected to unravel
new therapeutic targets and facilitate the design of more potent
superagonists.
SIGNIFICANCE
VitaminD nuclear receptor (VDR) acts as a ligand-dependent
transcription to control multiple biological responses, in-
cluding cellular antiproliferation, immune responses, and
bonemineralization. Intrinsic effects of 1a,25-dihydroxyvita-
min D3 (1a,25(OH)2D3)-mediated signal action are charac-
terized by exacerbated increase of calcium serum levels,
which limits its use for therapeutics applications. Numerous
1a,25(OH)2D3 analogs have been synthesized, but only a few
display significant clinical relevance. Therefore, the genera-
tion of new VDR ligands, based on the knowledge of the
crystal structure of VDR bound to its natural ligand, that ex-
hibit low calcemic side effects and/or antitumoral proper-
ties, is the topic of intensive research in the pharmaceutical
industry.
The present study reports the structure-based design of
a novel VDR superagonist ligand, its chemical synthesis,
and, to our knowledge, the first in vitro and in vivo tests.
In order to optimize the aliphatic side chain conformation,
we incorporated an oxolane ring between C17 and C23 of
the side chain and generated two 1a,25(OH)2D3 analogs,
AMCR277A(C23S) and AMCR277B(C23R), with opposite ste-
reochemistry at C23 of the oxolane moiety. We solved the
crystal structure of the ligand binding domain of the human
VDR liganded to each compound and determined that the
oxolane conformation is energetically more favorable for
AMCR277A compared with AMCR277B. Transcriptional
assays show that AMCR277A is a VDR superagonist,
whereas AMCR277B behaves like the natural ligand. This
specific property of AMCR277A is associated with a more
potent ability to reduce HL60 cell proliferation. However,
AMCR277A administration to mice, but not that of
AMCR277B, is as calcemic as the natural ligand. The crystal
structures provide an explanation for the superagonist ac-
tivity mechanism of this compound and a rational approach
to the design ofmore potent ligands, whichmay serve for di-
rect clinical applications and/or lead to the identification of
new therapeutic targets.
EXPERIMENTAL PROCEDURES
Synthesis of AMCR277A(C23S) and AMCR277B(23R)
The detailed synthesis of AMCR277A and AMCR277B are described in the
Supplemental Experimental Procedures and Figure S1.
Purification and Crystallization
Crystals of the hVDR LBD in complexes with AMCR277A and AMCR277B
were obtained with the mutant lacking 50 residues in the loop connecting
helices H1 and H3, used to solve the structure of the VDR LBD bound to
1a,25(OH)2D3 and several synthetic ligands (Rochel et al., 2000; Tocchini-
Valentini et al., 2001, 2004; Eelen et al., 2005; Hourai et al., 2006). Purification
and crystallization of hVDR LBD complexes with the apparently new ligands15, 383–392, April 2008 ª2008 Elsevier Ltd All rights reserved 389
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2001). Briefly, the LBD of hVDR (residues 118–427 [delta] 165–215) was cloned
in pET28b expression vector to obtain an N-terminal hexahistidine-tagged fu-
sion protein, and was overproduced in Escherichia Coli BL21 (DE3). Cells were
grown in LB medium and subsequently induced for 6 hr at 20C with 1 mM
isopropyl thio-b-D-galactoside. Protein purification included a metal affinity
chromatography step on a cobalt-chelating resin. The tag was removed with
thrombin and the protein further purified by gel filtration. The final protein buffer
was 10 mM Tris (pH 7.5), 100 mM NaCl, and 5 mM dithiothreitol. The protein
was concentrated to 10 mg/ml and incubated in the presence of a 5-fold
excess of the ligands. The purity and homogeneity of the protein were
assessed by SDS-PAGE and native-PAGE. Crystals of the complexes were
obtained at 4C by vapor diffusion in hanging drops. Crystals of VDR LBD-
1a,25(OH)2D3 complex were used for microseeding, and the seeds from serial
dilutions were introduced into freshly made drops. The reservoir solutions
contained 100 mM MES-KOH and 1.4 M ammonium sulfate at pH 6.0.
X-Ray Data Collection and Structure Determination
The crystals were cryoprotected with a solution containing the reservoir solu-
tion plus 30% glycerol and 5% PEG400, mounted in fiber loops and flash
cooled in liquid ethane at liquid N2 temperature. Data collection from a single
frozen crystal was performed at 100K at the beamline BM30 of the ESRF
(Grenoble, France). The crystals were isomorphous and belonged to the
orthorhombic space group P212121 with the unit cell parameters as specified
in Table 1. Data were integrated and scaled with the HKL2000 program pack-
age (Otwinowski and Minor, 1997).
The crystal structures of the VDR LBD complexes with AMCR277A and
AMCR277B were solved by molecular replacement by using the known
hVDR LBD-1a,25(OH)2D3 structure as a starting model and refined at 2.0
and 1.8 A˚ resolution, respectively. The omit maps from the refined atomic
model of VDR LBD were used to fit the ligands to their electron density, as
shown in Figure 3B. Anisotropic scaling and a bulk solvent correction and
restrained isotropic atomic B-factor refinement were used. The average
temperature factors for the ligands (14.3 and 14.1 A˚2 for AMCR277A
and AMCR277B, respectively) were lower than those for proteins (23.2 and
18.3 A˚2 for AMCR277A and AMCR277B, respectively).
Alternate cycles of maximum likelihood refinement and model fitting were
subsequently performed to generate the final models of the complexes. All
data were included in the refinement (no d cutoffs). All refined models showed
unambiguous chirality for the ligands and no Ramachandran plot outliers
according to PROCHECK. The final models of VDR-AMCR277A and VDR-
AMCR277B complexes contained 255 residues, with no clear electron density
for the first two N-terminal residues and the last four C-terminal residues, and
poor electron density for residues 375–377 in the loop connecting H9-H10.
Crystallographic data are summarized in Table 1. MOLREP, CNS-SOLVE,
and O programs were used for molecular replacement, structure refinement,
and model building (Vagin and Teplyakov, 2000; Bru¨nger et al., 1998; Jones
et al., 1991). For the structure comparison, Ca traces of the models were
superimposed with the lsq commands of O and default parameters. Figures
were generated with Pymol.
Transfection and Transactivation Assay
The hVDR LBD was subcloned into the pG4M-derived plasmid as a Gal fusion
protein. Transient transfection experiments for the analysis of VDR activation
were performed in 48-well plates by a standard calcium phosphate coprecipi-
tation technique, as previously described (Rochel et al., 2001). A total of 293
EBNA cells were seeded (6.0 3 104 cells/well) and incubated for 24 hr at
37C in DMEM containing 1g/l glucose, 10% fetal calf serum (FCS; Sigma),
gentamycine (Kalys), and 1 mg/ml G418 (geneticin). The 293 EBNA cells
were transiently transfected with 12.5 ng of Gal4-VDR LBD plasmid, 10 ng
of UAS-TATA-luciferase reporter plasmid, and 37.5 ng of PCH110 internal con-
trol recombinant expressing b-galactoside plasmid. Cells were incubated for 8
hr at 37C, then stimulated with the 1a,25(OH)2D3, AMCR277A, or AMCR277B
for 20 hr at indicated concentrations in fresh medium, and washed with PBS
prior to harvest in Passiv lysis buffer (Promega). Cell lysates were assayed
for luciferase and b-galactosidase activity. Luciferase activity for each sample
was normalized to b-galactosidase activity. All experiments were performed
in duplicate.390 Chemistry & Biology 15, 383–392, April 2008 ª2008 Elsevier LtdCell Culture and Differentiation
HL60 cells were cultured in complete RPMI with 10% FCS and 5% gentamy-
cine at 37C without CO2, as described previously, and plated at a density of
4 3 105 cells/ml and cultured for 96 hr in the presence of 1a,25(OH)2D3,
AMCR277A, or AMCR277B at concentrations ranging from 1 nM to 1 mM
(White et al., 2005). As control, cells were incubated with 0.7% ethanol solution
used to dissolve 1a,25(OH)2D3 and its analogs. Cells were counted with a
hemocytometer, and dead cells were excluded by trypan blue staining.
HL60 cell differentiation was determined by flow cytometry with PE-conju-
gated anti-human CD11c and FITC-conjugated anti-human CD14 antibodies
(PharMingen/BD Biosciences). Topro-3 (Molecular Probes) was added imme-
diately before laser excitation to exclude dead cells. Cells were analyzed on
a FACSCalibur (Becton Dickinson) and with FlowJo software (TreeStar Inc.).
Mice and Serum Calcium Quantitation
Animal protocols were approved by the Alsace regional ethics committee.
Male C57BL/6J mice were obtained from Charles River Laboratories, France
(l’Arbresle, France). Mice (6–7 wk old) were maintained in a temperature-
controlled (23C) facility with a 12 hr light/dark cycle, and were given free
access to food and water. Mice were fed with the standard mouse chow
(D03 SAFE; Augy, France) and tap water. The different a,25(OH)2D3 agonists
were dissolved in sesame oil and administered intraperitoneally every other
day at the indicated doses. Mice were fasted 4 hr prior to blood harvest, and
subsequent calcium measurements were determined with a kit supplied by
Table 1. Data Collection and Refinement Statistics
Ligand AMCR277A AMCR277B
Wavelength (A˚) 0.9794 0.9796







202.0 (2.072.0) 201.8 (1.861.8)
Unique reflections 21,276 28,589
Completeness (last shell) (%) 99.7 (97.8) 99.5 (97.3)
<I/d(I)> 30.2 (5.7) 26.7 (4.2)
Rmerge (last shell)








Rmsd bond angles (deg) 1.05 1.09
Nonhydrogen protein atoms 2019 2019
Nonhydrogen ligand atoms 32 32
Solvent molecules 159 193




a Rmerge: SjIh  <Ih>j/SIh, where Ih is the measurement of the intensity of
reflection h and <lh> is its mean value.
b Rcryst: SjFo  Fcj/SFo, where Fo and Fc are the observed and calculated
structure factor amplitudes, respectively.
c Rfree was calculated from 5% of all the data that were not used in the
refinement.All rights reserved
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Structure-Based Design of Vitamin D AnalogOlympus according to the manufacturer’s procedure on an Olympus AU400
analyzer (Olympus SA, Ringis, France) (Champy et al., 2004).
ACCESSION NUMBERS
The atomic coordinates and structure factors for VDR-AMCR277A and VDR-
AMCR277B have been deposited in the Protein Data Bank under ID codes
3CS4 and 3CS6, respectively.
SUPPLEMENTAL DATA
Supplemental Data include two figures and Supplemental Experimental
Procedures and can be found with this article online at http://www.
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